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and biofilms of C. albicans. We speculate that TLF may be used to enhance 
potency and fungal clearance in conjunction with antifungals against 
neonatal Candidiasis.
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Candida albiCans And Candida 
dubliniensis CEll-CEll SignAling: nEw 
PlAyERS in moRPhogEnESiS And Biofilm 
REgulATion
M. I. Martins, M. Henriques, J. Azeredo, R. Oliveira; University of 
Minho, Braga, PORTUGAL.
Signaling among microbial cells is thought to be part of community 
dynamics. In Candida albicans, cell-cell communication molecules are 
beginning to be highlighted, with a special focus on farnesol and tyrosol. 
The aim of this study was to identify signal molecules produced by biofilm-
grown Candida albicans and Candida dubliniensis, and to evaluate the 
impact of the production of signal molecules on cell morphogenesis and 
biofilm development. Biofilm supernatants, of both species, obtained at 
24, 48, 72 and 96 h of biofilm formation, were analyzed by headspace-
solid-phase microextraction and gas chromatography-mass spectrometry. 
It was found that supernatants fractions of C. albicans and C. dubliniensis 
contained isoamyl alcohol, 2-phenylethanol, 1-dodecanol, nerolidol, 
and farnesol. The physiological effect of the commercial (pro-analysis) 
formulation of these alcohols was evaluated on planktonic cell morphology 
and biofilm formation capability of both organisms. Treatment of 
planktonic cultures of both species with the tested alcohols revealed a role 
in morphogenesis control, inhibiting the transition of yeast to filamentous 
form by up to 50%. The ability of these compounds to regulate C. albicans 
and C. dubliniensis biofilm formation was assessed by adding the alcohols 
at 0h and 3 h of adherence and on 48 h biofilms. Biofilms were analysed 
in terms of total biomass by crystal violet staining and cellular activity by 
the reduction of a tetrazolium salt (XTT). The results indicate that besides 
farnesol other molecules regulate biofilm formation (at earlier stages) for 
both species, but not mature biofilms (48 h), which are not sensitive to 
any of the molecules assayed. Overall, the results show that C. albicans 
and C. dubliniensis tightly regulate their physiological behaviour through 
metabolites produced during growth, evidencing the complexity of C. 
albicans and C. dubliniensis signaling systems.
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ChAngES in ThE EPidEmiology of 
noSoComiAl CAndidEmiA fRom 
2001 To 2007 AT ThE mAyo CliniC 
jACKSonvillE
J. C. Mendez, J. J. Cawley, L. M. Brumble; Mayo Clinic 
Jacksonville, Jacksonville, FL.
Background: Candida has emerged as one of the most important nosocomial 
pathogens and is associated with significant morbidity, mortality and cost to 
the health system. The epidemiology of fungal infections has dramatically 
changed over the last 20 years worldwide. Candida species are the fourth 
most common cause of nosocomial bloodstream infections and the third 
most common cause of these infections in the ICU setting. Methods: We 
conducted a retrospective review of all the episodes of Candidemia at 
the Mayo Clinic Jacksonville/St. Luke’s Hospital from 2001 to 2007 to 
determine the changes in epidemiology and clinical implications in our 
institution. Species identification, distribution and susceptibilities were 
reviewed, analyzed and compared for the period of 2001 to 2007. 
Results: We found 314 episodes of Candidemia for the study period. 
Candida glabrata (36%) was the most frequent species identified followed 
Ten patients were receiving prophylaxis (5 fluconazole, 3 itraconazole, 1 
posaconazole, 1 amphotericin), five were receiving empirical antifungal 
therapy (2 liposomal amphotericin, 3 echinocandin), while 11 were not 
receiving any antifungal therapy. Before the acquisition of the antifungal 
sensitivities, the antifungal treatment was revised in 22 patients (85%). After 
the acquisition, we concluded that 20 patients (77%) were receiving proper 
antifungal therapy. Five patients (19%), all with lymphoid malignancies, 
died due to the fungemia (2 C.parapsilosis, 1 C.incospicus, 1 C.lusitaniae, 
and 1 Rhodotorula glutinis/C.lusitaniae). Two patients were not receiving 
proper therapy. DISCUSSION: Although fungal infections are very 
common in patients with hematological malignancies, proven fungemias are 
relatively uncommon, especially the breakthrough ones. It is notable that the 
incidence of C.albicans has decreased, with a relative increase of the other 
non-albicans species. Therapy according to species sensitivity results could 
improve the outcome, but unfortunately, due to the extended time necessary 
to acquire the antifungal sensitivities of the species, it is difficult to revise to 
a proper antifungal therapy on time, a fact that can be sometimes fatal.
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humAn REComBinAnT lACTofERRin iS 
SynERgiSTiC wiTh AmPhoTERiCin And 
fluConAzolE AgAinST PlAnKToniC 
CEllS And BiofilmS of C. albiCans
M. Pammi Venkatesh, R. Liang; Baylor College of Medicine, 
Houston, TX.
Candida is a common cause for neonatal sepsis and causes significant 
mortality, morbidity and health care costs. Lactoferrin, a component of milk 
and innate immunity, has broad-spectrum antimicrobial activity. 
Hypothesis: Talactoferrin (TLF, human recombinant lactoferrin) is 
synergistic with amphotericin and fluconazole, against planktonic and 
biofilm forms of clinical isolates of C. albicans. 
Methods: C. albicans strains; ATCC# 32354, a human isolate, and C100 and 
M 101, blood isolates from septic neonates, were used to determine 50% 
minimum inhibitory concentrations (MIC50) by the broth micro-dilution 
method for TLF, amphotericin and fluconazole as per CLSI guidelines, 
using XTT (tetrazoleum salt) reduction to determine the endpoints. C. 
albicans (ATCC# 32354) biofilms were formed on 96 well microtiter 
plates for 24 hrs. Biofilm formation and the uniformity of formation in all 
wells were confirmed by inverted microscopy and XTT reduction assay. 
Minimum biofilm eradication concentration for 50% inhibition (MBEC50) 
was determined for TLF, amphotericin and fluconazole. Combinations of 
TLF with amphotericin and fluconazole, for both planktonic and biofilms 
were tested by checkerboard method and XTT reduction. All experiments 
were done in duplicate on 2 days. Analyses: Combination indices (CI) 
were determined using the median effects equation using the software 
Calcusyn at 3 different dose effects at 50%, 75% and 90% inhibition (ED50, 
ED75 and ED90) at equipotency ratios (ratios of MIC50). CI < 1, >1, =1 
denotes synergy, antagonism and indifferent effect respectively. Results: 
For planktonic C. albicans; ATCC # 32354, C100 and M101, the MIC50 of 
TLF were 62.5, 250 and 250, of fluconazole 0.032, 0.25 and 0.25, and of 
amphotericin 0.03, 0.0625 and 0.0625 respectively (in μg/ml). The CI (in 
mean (SD)) at ED50, ED75 and ED90 for combination of TLF + fluconazole; 
against ATCC# 32354 were 0.47(0.021), 0.19(0.09) and 0.11(0.12), against 
C100 0.12(0.03), 0.06(0.05) and 0.04(0.04), and against M101 0.15(0.07), 
0.06(0.04) and 0.03 (0.02) respectively. For TLF + amphotericin, CI 
(mean (SD) at ED50, ED75 and ED90 were; for ATCC # 32354, 0.11 (0.08), 
0.11(0.08) and 0.12(0.05), for C100 0.23(0.12), 0.15(0.03) and 0.11(0.03) 
and for M101 were 0.38(0.06), 0.26 (0.01) and 0.21 (0.02) respectively. 
C. albicans ATCC# 32354 biofilms: MBEC50 of TLF, fluconazole and 
amphotericin were > 66400, 0.16 and 0.8 μg/ml respectively. The CI (in 
mean (SD)) at ED50, ED75 and ED90 for TLF + fluconazole were 0.25(0.01), 
0.19(0.01) and 0.19(0.09) and for TLF + amphotericin combination 
0.40(0.38), 0.28(0.21) and 0.25(0.12) respectively. Conclusion: TLF is 
synergistic with amphotericin B and fluconazole against planktonic forms 
